Stocktoria
Lyra Therapeutics, Inc. LYRA
Lyra Therapeutics, Inc. (LYRA) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $398,000 at a -7266.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LYRA | Lyra Therapeutics, Inc. | 2/9 | — | — | — |
| PLSE | PULSE BIOSCIENCES, INC. | 2/9 | -10.11 | — | — |
| QTEX | QTREX Quantum Ltd. | 2/9 | — | — | — |
| FOFA | FAMILY OFFICE OF AMERICA, INC. | 2/9 | -13.31 | — | — |
| SKYA | SkyAI, Inc. | 3/9 | — | — | — |
| CODX | Co-Diagnostics, Inc. | 1/9 | -16.26 | — | — |
| PAVM | PAVmed Inc. | 3/9 | — | 90.2 | — |
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
FAQ
Is LYRA financially healthy?
Lyra Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does LYRA pay a dividend?
No, Lyra Therapeutics, Inc. does not currently pay a dividend.
How profitable is LYRA?
In FY2025, Lyra Therapeutics, Inc. had a net margin of -7266.1%.
Is LYRA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lyra Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.